CAS 1293395-67-1

Formule : C22H22FN7O

InChI : InChI=1S/C22H22FN7O/c23-16-3-1-15(2-4-16)20-21(19-5-9-25-22(24)27-19)30(14-26-20)18-6-10-29(11-7-18)13-17-8-12-31-28-17/h1-5,8-9,12,14,18H,6-7,10-11,13H2,(H2,24,25,27)

Code InChI : XPWHRQHBPRSUAW-UHFFFAOYSA-N

SMILES : C1CN(CCC1N2C=NC(=C2C3=NC(=NC=C3)N)C4=CC=C(C=C4)F)CC5=NOC=C5

PF-5006739

CAS : 1293395-67-1

PF-5006739

Formule : C₂₂H₂₂FN₇O

Degré de pureté : ≥98%

Masse moléculaire : 419.45

Ref: 54-PC1032327

PF-5006739

CAS : 1293395-67-1

PF-5006739 is a selective CK1δ/ε inhibitor for psychiatric disorder and metabolic research.

Formule : C₂₂H₂₂FN₇O

Degré de pureté : 99.96%

Couleur et forme : Solid

Masse moléculaire : 419.4548

Ref: TM-T16507

4-(4-(4-Fluorophenyl)-1-(1-(isoxazol-3-ylmethyl)piperidin-4-yl)-1H-imidazol-5-yl)pyrimidin-2-amine

CAS : 1293395-67-1

Formule : C₂₂H₂₂FN₇O

Degré de pureté : 98%

Couleur et forme : Solid

Masse moléculaire : 419.4548

Ref: IN-DA000Z2N

PF 5006739

CAS : 1293395-67-1

PF 5006739 is a synthetic casein kinase 1 (CK1) inhibitor. It has been shown to inhibit the activity of CK1 in vitro and in vivo, which may be important for the treatment of cancers with mutations in CK1. PF 5006739 also has potential as a therapeutic for animal models of metabolic disorders and neurodegenerative diseases. It inhibits the activity of p38 MAP kinases, which are involved in inflammatory responses and cancer development. PF 5006739 is a potent inhibitor of adipose tissue casein kinase 1 (AT-CK1), which prevents the activation of lipolysis proteins such as hormone-sensitive lipase (HSL).

Formule : C₂₂H₂₂FN₇O

Degré de pureté : Min. 95%

Masse moléculaire : 419.46 g/mol

Ref: 3D-TBC39567